Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2019 Impact factor 1.556

Nuclear Science and Techniques ›› 2009, Vol. 20 ›› Issue (2): 106-110 doi: 10.13538/j.1001-8042/nst.20.106-110

• RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICIN • Previous Articles     Next Articles

Biodistribution characteristics of 188Re-TSC after TAE in rabbits bearing VX2 liver tumor

ZHANG Bin1,2,* WU Yiwei2 JIN Yonghai3 LIU Yizhi3 LUO Xianwen2 FAN Wo1   

  1. 1 School of Radiation Medicine and Public Health, Soochow University, Suzhou 215123, China 2 Department of Nuclear Medicine, the First Affiliated Hospital of Soochow University, Suzhou 215006, China 3 Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China
PDF ShareIt Export Citation
ZHANG Bin, WU Yiwei, JIN Yonghai, LIU Yizhi, LUO Xianwen, FAN Wo. Biodistribution characteristics of 188Re-TSC after TAE in rabbits bearing VX2 liver tumor.Nuclear Science and Techniques, 2009, 20(2): 106-110     doi: 10.13538/j.1001-8042/nst.20.106-110

Abstract:

188Re-tin sulfur colloid (TSC) was prepared to compare its biodistribution characteristics with 188Re-macroaggregates album (MAA) after transhepatic arterial embolization (TAE) in rabbits bearing VX2 liver tumor. Labeling efficiencies of the 188Re-TSC and 188Re-MAA were 99.94%±0.04% and 99.95%±0.03%, respectively, and they were stable for 72 h in human serum. Sintigraphy and biodistribution in 31 rabbits bearing VX2 liver tumor after transcatherter hepatic arterial injection of the radiopharmaceuticals were performed, and relevant activity accumulated mostly in the tumor. The percentage of the injected dose per gram of wet tissue (%ID/g) of 188Re-TSC and 188Re-MAA were calculated. Tumor uptake of 188Re-TSC at 1 h and 24 h were 24.32%±11.93% and 21.88%±18.29%, and the radioactive ratios of tumor/liver were 70.89±19.58 and 17.42±13.96, respectively. Tumor uptake of 188Re-MAA at 1 h and 24 h were 38.78%±30.23% and 15.98%±26.64%, and the radioactive ratio of tumor/liver of 188Re-MAA were 39.71±25.06 and 8.13±4.61, respectively. 188Re-TSC is a potential radiopharmaceutical for the therapy of tumors.

Key words: 188Re, Tin sulfur colloid (TSC), Transhepatic arterial embolization (TAE), Liver tumor